Granted Patent
B2
US 12,403,468 · App. 18/487,884 · Granted Sep 2, 2025
Fluid connector
Inventors:
Vladimir Azersky (San Jose, CA); Fabian Gerlinghaus (South San Francisco, CA); Daniele Malleo (Menlo Park, CA); Brian Alexander Pesch (San Francisco, CA); Bharat S. Thakkar (Campbell, CA); Wilson Wai Toy (San Francisco, CA)
Assignee:
Cellares Corporation
B01L3/502715A61L2/04A61L2/20A61L2/206A61L2/208B01J19/004B01L13/00C12M23/44C12M23/50C12M41/48C12N5/00C12N5/0081A61L2/08A61L2202/11A61L2202/122A61L2202/123A61L2202/14B01J2219/0002B01J2219/0074B01L2200/027B01L2300/049
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein are cell processing systems, devices, and methods thereof. A system for cell processing may comprise a plurality of instruments each independently configured to perform one or more cell processing operations upon a cartridge, and a robot capable of moving the cartridge between each of the plurality of instruments.
Claims (33)
1. A system for processing cell products in parallel comprising:
an enclosed workcell comprising:
a first instrument for cell processing
a second instrument for cell processing;
a robotic arm coupled to a linear rail; and
an enclosed cartridge configured to receive a cell product and to independently interface with the first and second instruments, wherein the cartridge is coupled to one or more fluidic pathways for transferring fluid into the cartridge; and
wherein the robotic arm is configured to move the enclosed cartridge between the first instrument and the second instrument.
2. The system of claim 1 , wherein the enclosed workcell further comprises a feedthrough configured to receive the enclosed cartridge.
3. The system of claim 2 , wherein the feedthrough is in fluid communication with a sterilization system.
4. The system of claim 3 , wherein the sterilization system is configured to perform a sterilization procedure when the enclosed cartridge is within the feedthrough.
5. The system of claim 4 , wherein the sterilization procedure comprises circulating a sterilant within the feedthrough.
6. The system of claim 5 , wherein the sterilant comprises one or both of heated air and vaporized hydrogen peroxide.
7. The system of claim 1 , wherein each of the first and second instruments comprise a bioreactor instrument, a cell selection instrument, a magnetic-activated cell selection instrument, a sorting instrument, an electroporation instrument, and a counterflow centrifugal elutriation (CCE) instrument.
8. The system of claim 7 , wherein the first and second instruments are different.
9. The system of claim 1 , wherein the enclosed cartridge comprises one or more of a bioreactor module, a cell selection module, a magnetic-activated cell selection module, a sorting module, a fluorescence activated cell sorting (FACS) module, an electroporation module, a counterflow centrifugal elutriation (CCE) module.
10. The system of claim 1 further comprising a sterile liquid transfer device (SLTD) configured to store one or more fluids.
11. The system of claim 10 , wherein the SLTD comprises a portable container.
12. The system of claim 10 , wherein the one or more fluids comprise one or more of a reagent and a cell culture medium.
13. The system of claim 10 , wherein the SLTD is configured to be stored in a reagent vault of the workcell.
14. The system of claim 13 , wherein the robotic arm is further configured to move the SLTD from the reagent vault to the first or second instrument of the workcell.
15. The system of claim 14 , wherein the first or second instrument of the workcell comprises a sterile liquid transfer instrument (SLTI).
16. The system of claim 15 , wherein the SLTI comprises a fluid connector configured to direct a fluid of the one or more fluids into the enclosed cartridge.
17. A system for processing cell products in parallel comprising:
an enclosed workcell comprising:
a first instrument for cell processing
a second instrument for cell processing;
a robotic arm; and
a feedthrough for sterilization; and
an enclosed cartridge configured to receive a cell product and to independently interface with the first and second instruments,
wherein the robotic arm is configured to move the enclosed cartridge between the first instrument and the second instrument.
18. The system of claim 17 , wherein the sterilization occurs via a sterilization system coupled to the feedthrough.
19. The system of claim 18 , wherein the sterilization system comprises a sterilant source and a pump.
20. The system of claim 19 , wherein the sterilization system is configured to circulate a sterilant within the feedthrough.
Assignments (3)
SECURITY INTEREST
Recorded May 5, 2026
From: CELLARES CORPORATION
To: TRINITY CAPITAL INC.
Reel/Frame 075545/0558 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 12, 2024
From: GERLINGHAUS, FABIAN; MALLEO, DANIELE; PESCH, BRIAN ALEXANDER; THAKKAR, BHARAT S.; TOY, WILSON WAI
To: CELLARES CORPORATION
Reel/Frame 068574/0795 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 12, 2024
From: AZERSKY, VLADIMIR
To: CELLARES CORPORATION
Reel/Frame 068574/0824 →
Continuity (8)
Provisional Application
63093038
· Oct 16, 2020
Provisional Application
62987745
· Mar 10, 2020
References Cited (333)
US 3728227A
· Elson et al.
· 1973
[cited by applicant]
US 4234023A
· Sogi et al.
· 1980
[cited by applicant]
US 4696902A
· Bisconte
· 1987
[cited by applicant]
US 4751184A
· Higo et al.
· 1988
[cited by applicant]
US 4839292A
· Cremonese
· 1989
[cited by applicant]
US 4911833A
· Schoendorfer et al.
· 1990
[cited by applicant]
US 5058619A
· Zheng
· 1991
[cited by applicant]
US 5656491A
· Cassani et al.
· 1997
[cited by applicant]
US 6102678A
· Peclat
· 2000
[cited by applicant]
US 6267559B1
· Mossman et al.
· 2001
[cited by applicant]
US 6649419B1
· Anderson
· 2003
[cited by applicant]
US 6891182B2
· Watari et al.
· 2005
[cited by applicant]
US 7521224B2
· Johnson et al.
· 2009
[cited by applicant]
US 7550287B2
· Hibino et al.
· 2009
[cited by applicant]
US 7745209B2
· Martin et al.
· 2010
[cited by applicant]
US 7816128B2
· Nakashima et al.
· 2010
[cited by applicant]
US 8158426B2
· Wilson et al.
· 2012
[cited by applicant]
US 8158427B2
· Wilson et al.
· 2012
[cited by applicant]
US 8168432B2
· Wilson et al.
· 2012
[cited by applicant]
US 8273572B2
· Martin et al.
· 2012
[cited by applicant]
US 8415144B2
· Wilson et al.
· 2013
[cited by applicant]
US 8440458B2
· Zijlstra et al.
· 2013
[cited by applicant]
US 8470589B2
· Martin et al.
· 2013
[cited by applicant]
US 8492140B2
· Smith et al.
· 2013
[cited by applicant]
US 8546142B2
· Martin et al.
· 2013
[cited by applicant]
US 8697443B2
· Wilson et al.
· 2014
[cited by applicant]
US 8727132B2
· Miltenyi et al.
· 2014
[cited by applicant]
US 8809044B2
· Wilson
· 2014
[cited by applicant]
US 8846399B2
· Martin et al.
· 2014
[cited by applicant]
US 8956860B2
· Vera et al.
· 2015
[cited by applicant]
US 9040290B2
· Martin et al.
· 2015
[cited by applicant]
US 9045721B2
· Martin et al.
· 2015
[cited by applicant]
US 9080149B2
· Bosio et al.
· 2015
[cited by applicant]
US 9255243B2
· Wilson et al.
· 2016
[cited by applicant]
US 9279099B2
· Okano et al.
· 2016
[cited by applicant]
US 9290730B2
· Martin et al.
· 2016
[cited by applicant]
US 9410114B2
· Wilson et al.
· 2016
[cited by applicant]
US 9441192B2
· Wilson et al.
· 2016
[cited by applicant]
US 9499780B2
· Smith et al.
· 2016
[cited by applicant]
US 9534195B2
· Smith et al.
· 2017
[cited by applicant]
US 9556485B2
· Lin et al.
· 2017
[cited by applicant]
US 9567565B2
· Vera et al.
· 2017
[cited by applicant]
US 9597355B2
· Magnant
· 2017
[cited by applicant]
US 9625463B2
· Miltenyi et al.
· 2017
[cited by applicant]
US 9701932B2
· Smith et al.
· 2017
[cited by applicant]
US 9732317B2
· Wilson
· 2017
[cited by applicant]
US 9783768B2
· Larcher et al.
· 2017
[cited by applicant]
US 9845451B2
· Martin et al.
· 2017
[cited by applicant]
US 20020146817A1
· Cannon et al.
· 2002
[cited by applicant]
US 20030030272A1
· Johnson et al.
· 2003
[cited by applicant]
US 20030031542A1
· Hamel et al.
· 2003
[cited by applicant]
US 20040121454A1
· Jury et al.
· 2004
[cited by applicant]
US 20050070018A1
· Johnson et al.
· 2005
[cited by applicant]
US 20050186671A1
· Cannon et al.
· 2005
[cited by applicant]
US 20050260743A1
· Drake et al.
· 2005
[cited by applicant]
US 20060194193A1
· Tsuruta et al.
· 2006
[cited by applicant]
US 20060257999A1
· Chang et al.
· 2006
[cited by applicant]
US 20070185472A1
· Baumfalk et al.
· 2007
[cited by applicant]
US 20080057568A1
· Kan et al.
· 2008
[cited by applicant]
US 20080176318A1
· Wilson et al.
· 2008
[cited by applicant]
US 20090042281A1
· Chang et al.
· 2009
[cited by applicant]
US 20090053799A1
· Chang-Yen et al.
· 2009
[cited by applicant]
US 20090247417A1
· Haas et al.
· 2009
[cited by applicant]
US 20100130732A1
· Chung et al.
· 2010
[cited by applicant]
US 20100151571A1
· Vukasinovic et al.
· 2010
[cited by applicant]
US 20100301071A1
· Alstad et al.
· 2010
[cited by applicant]
US 20110003380A1
· Miltenyi et al.
· 2011
[cited by applicant]
US 20110223064A1
· Katsumi et al.
· 2011
[cited by applicant]
US 20110229927A1
· Larsen et al.
· 2011
[cited by applicant]
US 20110262896A1
· Blecka et al.
· 2011
[cited by applicant]
US 20120138156A1
· Hofman et al.
· 2012
[cited by applicant]
US 20120148415A1
· Brueckner
· 2012
[cited by applicant]
US 20120283867A1
· Gelbman et al.
· 2012
[cited by applicant]
US 20120293338A1
· Chaffey et al.
· 2012
[cited by applicant]
US 20130078624A1
· Holmes et al.
· 2013
[cited by applicant]
US 20130115617A1
· Wilson
· 2013
[cited by applicant]
US 20130132006A1
· Gwynn et al.
· 2013
[cited by applicant]
US 20130189120A1
· Nelson et al.
· 2013
[cited by applicant]
US 20140309795A1
· Norton et al.
· 2014
[cited by applicant]
US 20150037803A1
· Park et al.
· 2015
[cited by applicant]
US 20150307829A1
· Dedry et al.
· 2015
[cited by applicant]
US 20150336096A1
· Smith et al.
· 2015
[cited by applicant]
US 20160060680A1
· Buse et al.
· 2016
[cited by applicant]
US 20160161516A1
· Fritchie et al.
· 2016
[cited by applicant]
US 20160208216A1
· Vera et al.
· 2016
[cited by applicant]
US 20160244714A1
· Spuhler et al.
· 2016
[cited by applicant]
US 20160303563A1
· Granier et al.
· 2016
[cited by applicant]
US 20160320381A1
· Holmes et al.
· 2016
[cited by applicant]
US 20160320422A1
· Fritchie et al.
· 2016
[cited by applicant]
US 20170058527A1
· Williams et al.
· 2017
[cited by applicant]
US 20170239420A1
· Wells
· 2017
[cited by applicant]
US 20170307502A1
· Mason et al.
· 2017
[cited by applicant]
US 20170313977A1
· Wilson
· 2017
[cited by applicant]
US 20170321226A1
· Gill et al.
· 2017
[cited by applicant]
US 20170348525A1
· Sano et al.
· 2017
[cited by applicant]
US 20170362554A1
· Martin et al.
· 2017
[cited by applicant]
US 20180031592A1
· Dority
· 2018
[cited by applicant]
US 20180051243A1
· Hogan et al.
· 2018
[cited by applicant]
US 20180078935A1
· Hung et al.
· 2018
[cited by applicant]
US 20180185849A1
· Kaplan et al.
· 2018
[cited by applicant]
US 20180196918A1
· Sadowski et al.
· 2018
[cited by applicant]
US 20190212233A1
· Jovanovich et al.
· 2019
[cited by applicant]
US 20190275519A1
· Castillo et al.
· 2019
[cited by applicant]
US 20190292510A1
· Tandon et al.
· 2019
[cited by applicant]
US 20190293673A1
· Wescott et al.
· 2019
[cited by applicant]
US 20190316120A1
· Masquelier et al.
· 2019
[cited by applicant]
US 20190330579A1
· Guenat et al.
· 2019
[cited by applicant]
US 20200009557A1
· Frigard et al.
· 2020
[cited by applicant]
US 20200025782A1
· Ahlfors
· 2020
[cited by examiner]
US 20200048599A1
· Firouzi et al.
· 2020
[cited by applicant]
US 20200095550A1
· Vera et al.
· 2020
[cited by applicant]
US 20200159198A1
· Kapre et al.
· 2020
[cited by applicant]
US 20200224147A1
· Rogers et al.
· 2020
[cited by applicant]
US 20200283713A1
· Ball et al.
· 2020
[cited by applicant]
US 20200292552A1
· Miltenyi et al.
· 2020
[cited by applicant]
US 20200353004A1
· Nowak et al.
· 2020
[cited by applicant]
US 20200368411A1
· Camisani et al.
· 2020
[cited by applicant]
US 20200399578A1
· Corso et al.
· 2020
[cited by applicant]
US 20200406221A1
· Dabrowski et al.
· 2020
[cited by applicant]
US 20210032583A1
· Smith et al.
· 2021
[cited by applicant]
US 20210035655A1
· Tanouchi et al.
· 2021
[cited by applicant]
US 20210079344A1
· Bosio et al.
· 2021
[cited by applicant]
US 20210147807A1
· Lickert et al.
· 2021
[cited by applicant]
US 20210253997A1
· Wilson
· 2021
[cited by applicant]
US 20210269755A1
· Smith et al.
· 2021
[cited by applicant]
US 20210283565A1
· Gerlinghaus et al.
· 2021
[cited by applicant]
US 20210284948A1
· Hauwaerts et al.
· 2021
[cited by applicant]
US 20210301239A1
· Natsume et al.
· 2021
[cited by applicant]
US 20210324318A1
· Parietti et al.
· 2021
[cited by applicant]
US 20220002652A1
· Patrick et al.
· 2022
[cited by applicant]
US 20220003796A1
· Ahlfors
· 2022
[cited by applicant]
US 20220121181A1
· Sobalvarro et al.
· 2022
[cited by applicant]
US 20220143610A1
· Biz et al.
· 2022
[cited by applicant]
US 20220150650A1
· Rucker
· 2022
[cited by applicant]
US 20220163438A1
· Klas et al.
· 2022
[cited by applicant]
US 20220259546A1
· Blanchard
· 2022
[cited by applicant]
US 20220325219A1
· Parietti et al.
· 2022
[cited by applicant]
US 20220325240A1
· Mcfarland et al.
· 2022
[cited by applicant]
US 20220347683A1
· Thakkar et al.
· 2022
[cited by applicant]
US 20230051840A1
· Kelso et al.
· 2023
[cited by applicant]
US 20230149922A1
· Thakkar et al.
· 2023
[cited by applicant]
US 20230321650A1
· Azersky et al.
· 2023
[cited by applicant]
US 20230415154A1
· Pesch et al.
· 2023
[cited by applicant]
US 20240018955A1
· Hannah et al.
· 2024
[cited by applicant]
US 20240167466A1
· Paraluppi
· 2024
[cited by applicant]
US 20240254426A1
· Elpel et al.
· 2024
[cited by applicant]
US 20240255537A1
· Malleo et al.
· 2024
[cited by applicant]
US 20240279588A1
· Malleo et al.
· 2024
[cited by applicant]
US 20240318116A1
· Chang et al.
· 2024
[cited by applicant]
US 20240326043A1
· Gerlinghaus et al.
· 2024
[cited by applicant]
US 20240377420A1
· Cesarek
· 2024
[cited by applicant]
US 20240402206A1
· Boppart et al.
· 2024
[cited by applicant]
US 20250059492A1
· Beban et al.
· 2025
[cited by applicant]
US 20250066708A1
· Burkeen et al.
· 2025
[cited by applicant]
CN 104203333A
· 2014
[cited by applicant]
CN 108660060A
· 2018
[cited by applicant]
EP 0246912A2
· 1987
[cited by applicant]
EP 0991389A1
· 2000
[cited by applicant]
EP 0824380B1
· 2002
[cited by applicant]
EP 3134512B1
· 2019
[cited by applicant]
EP 2809449B1
· 2019
[cited by applicant]
EP 3359294B1
· 2020
[cited by applicant]
EP 3928867A1
· 2021
[cited by applicant]
GB 2268187A
· 1994
[cited by applicant]
JP 2007325586A
· 2007
[cited by applicant]
KR 20130018286A
· 2013
[cited by applicant]
KR 20220131302A
· 2022
[cited by applicant]
WO WO9320440A1
· 1993
[cited by applicant]
WO WO2006102416A2
· 2006
[cited by applicant]
WO WO2006112870A1
· 2006
[cited by applicant]
WO WO2006118282A1
· 2006
[cited by applicant]
WO WO2007139742A1
· 2007
[cited by applicant]
WO WO2009072003A2
· 2009
[cited by applicant]
WO WO2017041051A1
· 2017
[cited by applicant]
WO WO2017123663A1
· 2017
[cited by applicant]
WO WO2018015561A1
· 2018
[cited by applicant]
WO WO2018102471A1
· 2018
[cited by applicant]
WO WO2020009700A1
· 2020
[cited by applicant]
WO WO2020014264A1
· 2020
[cited by applicant]
WO WO2021168368A1
· 2021
[cited by applicant]
WO WO2021183687A2
· 2021
[cited by applicant]
WO WO2021212124A1
· 2021
[cited by applicant]
WO WO2024102996A1
· 2024
[cited by applicant]
WO WO2024112702A1
· 2024
[cited by applicant]
WO WO2024152008A1
· 2024
[cited by applicant]
WO WO2024197093A2
· 2024
[cited by applicant]
WO WO2024206703A1
· 2024
[cited by applicant]
WO WO2024233080A1
· 2024
[cited by applicant]
WO WO2024249904A1
· 2024
[cited by applicant]
WO WO2025007051A2
· 2025
[cited by applicant]
WO WO2025038974A1
· 2025
[cited by applicant]
WO WO2025041046A1
· 2025
[cited by applicant]
WO WO2025041047A1
· 2025
[cited by applicant]
WO WO2025041064A2
· 2025
[cited by applicant]
ChargePoint (2021). Aseptic split butterfly valve 10-6 sterility assurance, located at https://www.thechargepoint.com/products/aseptic-split-butterfly-valve-10-6-sterility-assurance/, 2 total pages.
[cited by applicant]
CPC (2014). “6 traits of non-spill: How quick disconnect couplings evolved for low-pressure fluid handling,” White Paper 8004, 4 total pages.
[cited by applicant]
CPC (2014). “How single-use connections advance aseptic processing: Increased process flexibility and reliability, reduced costs,” White Paper 7004, 6 total pages.
[cited by applicant]
CPC (2018). Comparison Guide: Tube Welders and Aseptic Connectors, Technical Guide 7009, 3 total pages.
[cited by applicant]
EMD Millipore (2015). “Lynx® S2S Connector—Low temperature compatibility (-80″C),” 4 total pages.
[cited by applicant]
Final Office Action mailed on Apr. 28, 2022, for U.S. Appl. No. 17/198,134, filed Mar. 10, 2021, 11 pages.
[cited by applicant]
Final Office Action mailed on Apr. 28, 2022, for U.S. Appl. No. 17/331,554, filed May 26, 2021, 16 pages.
[cited by applicant]
Final Office Action mailed on Jul. 31, 2023, for U.S. Appl. No. 17/331,554, filed May 26, 2021, 19 pages.
[cited by applicant]
Final Office Action mailed on Mar. 31, 2023, for U.S. Appl. No. 17/579,478, filed Jan. 19, 2022, 8 pages.
[cited by applicant]
Garcia, P.A. et al. (2016). “Microfluidic screening of electric fields for electroporation,” Sci. Rep. 6:21238, 11 pages.
[cited by applicant]
Genetic Engineering & Biotechnology News (2006). “Thermal welding for sterile connections,” located at https://www.genengnews.com/magazine/47/thermal-welding-for-sterile-connections/, 5 total pages.
[cited by applicant]
International Search Report mailed on Oct. 13, 2021, for PCT Application No. PCT/US2021/021773, filed on Mar. 10, 2021, 13 pages.
[cited by applicant]
Jain, S. et al. (2011). “The complete automation of cell culture: improvements for high-throughput and high-content screening,” J. Biomol. Screen 16:932-939.
[cited by applicant]
Kato, R. et al. (2010). “A Compact, Automated Cell Culture System for Clinical Scale Cell Expansion from Primary Tissues,” Tissue Engineering: Part C 16:947-956.
[cited by applicant]
Kempner, M.E. and Felder, R.A., “A review of cell culture automation”. JALA: Journal of the Association for Laboratory Automation (Apr. 2002); 7(2): 56-62.
[cited by applicant]
Kino-Oka, M. et al. (2005). “Bioreactor Design for Successive Culture of Anchorage-Dependent Cells Operated in an Automated Manner,” Tissue Engineering 11:535-545.
[cited by applicant]
Knoll, A. et al. (2004). “Flexible automation of cell culture and tissue engineering tasks,” Biotechnol. Prog. 20:1825-1835.
[cited by applicant]
Lutkemeyer, D. et al. (2000). “First steps in robot automation of sampling and sample management during cultivation of mammalian cells in pilot scale,” Biotechnol. Prog. 16:822-828.
[cited by applicant]
MEDInstill (2021). INTACT™ Connectors, located at https://www.medinstill.com/intactconnectors.php, 1 total page.
[cited by applicant]
Millipore® (2020). “Technical Brief—Choosing the right sterile connector based on design and sterility test results,” 4 total pages.
[cited by applicant]
Millipore Sigma (2020). “Lynx® CDR Connectors,” Datasheet, 4 total pages.
[cited by applicant]
Millipore Sigma (2021). Lynx® CDR Connectors, located at https://www.emdmillipore.com/US/en/product/Lynx-CDR-Connectors,MM_NF-C188801, 2 total pages.
[cited by applicant]
Non-Final Office Action mailed on Dec. 22, 2022, for U.S. Appl. No. 17/579,478, filed Jan. 19, 2022, 8 pages.
[cited by applicant]
Non-Final Office Action mailed on Jun. 26, 2023, for U.S. Appl. No. 17/198,134, filed Mar. 10, 2021, 15 pages.
[cited by applicant]
Non-Final Office Action mailed on Dec. 3, 2021, for U.S. Appl. No. 17/331,556, filed May 26, 2021, 9 pages.
[cited by applicant]
Non-Final Office Action mailed on Feb. 3, 2022, for U.S. Appl. No. 17/198,134, filed Mar. 10, 2021, 5 pages.
[cited by applicant]
Non-Final Office Action mailed on Mar. 16, 2023, for U.S. Appl. No. 17/331,554, filed May 26, 2021, 16 pages.
[cited by applicant]
Non-Final Office Action mailed on Oct. 28, 2021, for U.S. Appl. No. 17/331,554, filed May 26, 2021, 11 pages.
[cited by applicant]
Non-Final Office Action mailed on Oct. 6, 2021, for U.S. Appl. No. 17/198,134, filed Mar. 10, 2021, 7 pages.
[cited by applicant]
Non-Final Office Action mailed on Sep. 13, 2023, for U.S. Appl. No. 18/141,329, filed Apr. 28, 2023, 7 pages.
[cited by applicant]
Notice of Allowance mailed on Mar. 22, 2023, for U.S. Appl. No. 17/992,784, filed Nov. 22, 2022, 8 pages.
[cited by applicant]
Notice of Allowance mailed on Jul. 18, 2023, for U.S. Appl. No. 17/849,422, filed Jun. 24, 2022, 8 pages.
[cited by applicant]
Notice of Allowance mailed on Jul. 25, 2023, for U.S. Appl. No. 17/579,478, filed Jan. 19, 2022, 8 pages.
[cited by applicant]
Notice of Allowance mailed on Jun. 8, 2023, for U.S. Appl. No. 17/849,422, filed Jun. 24, 2022, 8 pages.
[cited by applicant]
Notice of Allowance mailed on Mar. 1, 2022, for U.S. Appl. No. 17/331,556, filed May 26, 2021, 8 pages.
[cited by applicant]
Notice of Allowance mailed on Oct. 4, 2023, for U.S. Appl. No. 18/141,329, filed Apr. 28, 2023, 8 pages.
[cited by applicant]
Qu, B., et al., “Droplet Electroporation in Microfluidics for Efficient Cell Transformation with or without Cell Wall Removal,” Lab Chip, 2012, vol. 12, pp. 4483-4488.
[cited by applicant]
Saint Gobain (2017). “Pure-Fit® SC—Secure aseptic connections,” Brochure, 5 total pages.
[cited by applicant]
Sartorius Stedim Biotech (2011). “Opta® SFT,” 4 total pages.
[cited by applicant]
Schwartz C, “Optimizing Cell Separation with Beckman Coulter's Centrifugal Elutriation System,” Beckmann Coulter Life Sciences, 2014, 6 total pages.
[cited by applicant]
SeriesLock™ (2021). Features and Specifications, located at https://serieslock.com/, 5 total pages.
[cited by applicant]
Shi, Y. et al. (1992). “Performance of Mammalian Cell Culture Bioreactor with a New Impeller Design,” Biotechnology and Bioengineering 40:260-270.
[cited by applicant]
Steris (2018). “A compilation of material compatibilities with vaporized hydrogen peroxide,” 2 total pages.
[cited by applicant]
Steris (2018). “Sterility assurance levels (SALS): Irradiation,” 3 total pages.
[cited by applicant]
Steris (2020). “Overview of sterilization technology comparison,” 1 total page.
[cited by applicant]
Strahlendorf, K.A. et al. (2009). “Bio Pharm International—A review of sterile connectors,” vol. 2009 Supplement, Issue 8, located at https://www.biopharminternational.com/view/review-sterile-connectors, 9 total pages.
[cited by applicant]
Written Opinion of the International Searching Authority mailed on Oct. 13, 2021, for PCT Application No. PCT/US2021/021773, filed on Mar. 10, 2021, 20 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/331,554 mailed Aug. 29, 2024, 18 pages.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2024/025064 mailed Sep. 6, 2024, 17 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2023/080593 dated Mar. 21, 2024, 12 pages.
[cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2024/011486 dated May 24, 2024, 12 pages.
[cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/US2024/022079 dated Jul. 17, 2024, 19 pages.
[cited by applicant]
Invitation to Pay Additional fees for International Application No. PCT/US2024/025064, mailed Jul. 16, 2024, 12 pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/652,602 mailed Jul. 17, 2024, 30 pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/731,095 mailed Aug. 8, 2024, 24 pages.
[cited by applicant]
Non-Final Office Action mailed on Apr. 24, 2024, for U.S. Appl. No. 17/331,554, filed May 26, 2021, 17 pages.
[cited by applicant]
Non-Final Office Action mailed on May 14, 2024, for U.S. Appl. No. 18/611,632, filed Mar. 20, 2024, 13 pages.
[cited by applicant]
Notice of Allowance (Corrected) mailed on Sep. 5, 2024, for U.S. Appl. No. 18/611,632, filed Mar. 20, 2024, 6 pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 18/611,632 mailed Aug. 26, 2024, 9 pages.
[cited by applicant]
Notice of Allowance mailed on Apr. 11, 2024, for U.S. Appl. No. 17/198,134, filed Mar. 10, 2021, 9 pages.
[cited by applicant]
Pharma Japan, “Astellas Set to Cut Development Time with Cell Culture Robot, Eyes 4 Billion Yen Profit per Product” Aug. 9, 2023, 3 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 18/652,602 mailed Nov. 1, 2024, 29 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 18/731,095 mailed Nov. 26, 2024, 31 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 18/799,963 mailed Jan. 30, 2025, 10 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2024/058106 mailed Jan. 21, 2025, 13 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2024/058148 mailed Mar. 3, 2025, 21 pages.
[cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/IB2024/058105 mailed Dec. 16, 2024, 12 pages.
[cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2024/022079 mailed Sep. 12, 2024, 25 pages.
[cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2024/032062 mailed Sep. 6, 2024, 15 pages.
[cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2024/042795 mailed Dec. 16, 2024, 11 pages.
[cited by applicant]
Invitation to Pay Additional fees for International Application No. PCT/IB2024/058148, mailed Jan. 2, 2025, 13 pages.
[cited by applicant]
Invitation to Pay Additional fees for International Application No. PCT/US2024/020809, mailed Jan. 27, 2025, 17 pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/244,051 mailed Oct. 9, 2024, 10 pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/638,658 mailed on Nov. 22, 2024, 13 pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/731,095 mailed Mar. 6, 2025, 34 pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/759,602 mailed Feb. 20, 2025, 15 pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/759,602 mailed Nov. 8, 2024, 10 pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/792,358 mailed on Nov. 6, 2024, 5 pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/799,963 mailed Sep. 30, 2024, 9 pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/810,386 mailed Nov. 18, 2024, 8 pages.
[cited by applicant]
Non-Final Office action for U.S. Appl. No. 18/920,607 mailed Feb. 28, 2025, 10 pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/988,628 mailed Mar. 3, 2025, 19 pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/331,554 mailed Mar. 5, 2025, 8 pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 18/792,358 mailed on Mar. 3, 2025, 8 pages.
[cited by applicant]
Notice of allowance for U.S. Appl. No. 18/792,360 mailed Mar. 4, 2025, 9 pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 18/792,360 mailed on Jan. 29, 2025, 9 pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 18/810,388 mailed Jan. 21, 2025, 8 pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 18/810,388 mailed on Oct. 9, 2024, 9 pages.
[cited by applicant]
Notice of allowance for U.S. Appl. No. 18/811,490 mailed Feb. 26, 2025, 8 pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 18/811,490 mailed on Dec. 12, 2024, 8 pages.
[cited by applicant]
U.S. Appl. No. 29/898,923, filed Aug. 2, 2023, by Gerlinghaus et al.
[cited by applicant]
Cited By (2)